
501 - 1000 employees
Founded 2014
🧬 Biotechnology
💊 Pharmaceuticals
💰 $350M Post-IPO Equity - Autolus on 2024-02
Biotechnology • Pharmaceuticals
Autolus Therapeutics is a clinical-stage biotechnology company developing next-generation autologous CAR T cell therapies for cancer and autoimmune diseases. The company applies advanced cell programming, proprietary viral vectors, and semi-automated T cell manufacturing to engineer precision CAR T products, and is advancing a pipeline that includes programs for hematological malignancies, solid tumors, and autoimmune indications. Autolus emphasizes integrated development and commercialization efforts, clinical trials, and publication of its research.
🔥 10 minutes ago
Vice President, Cell Therapy leading the commercial strategies for Autolus. Engaging with regional directors and managing corporate relationships with treatment centers across the U.S.